Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: A long term follow-up study

Bosselmann, Helle; Egstrup, Michael; Rossing, Kasper; Gustafsson, Ida; Gustafsson, Finn; Tønder, Niels; Kistorp, Caroline; Goetze, Jens P.; Schou, Morten

doi:10.1016/j.ijcard.2013.10.064

Cited by 33 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ADM also has diagnostic and prognostic value alongside the natriuretic peptides in acute dyspnoea and in chronic heart failure (12)(13)(14)(15)(16)(17)(18)(19)(20), and in diastolic dysfunction (21). In post-AMI patients with new heart failure (9), patients with established heart failure (12,22), and patients presenting with acute dyspnoea in emergency settings (13)(14)(15)23), MRproADM has been shown to have independent prognostic significance for major adverse cardiovascular outcomes. It is also predictive of adverse outcomes in community patients with symptoms of heart failure (24).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Adrenomedullin in Patients With Heart Failure and With Myocardial Infarction

Yuyun

Narayan

2015

The American Journal of Cardiology

View full text Add to dashboard Cite

Highlights-This systematic review shows that adrenomedullin is an independent predictor of death in patients with heart failure, as well as MACE and death in patients who have suffered an acute myocardial infarction.-Quantification of this peptide might contribute to improved risk stratification in settings of heart failure and myocardial infarction. ABSTRACTWe undertook this systematic review to determine the prognostic significance of adrenomedullin (ADM) in heart failure and acute myocardial infarction (AMI) patients.Given the difficulty in measuring mature ADM, its surrogate, mid-regional proadrenomedullin (MRproADM), has been used in most studies. 1 nmol/l increase in MRproADM was associated with HR for MACE ranging from 1.78 to 4.10 (CI 1.20 -10.12), while log10 of MRproADM had hazard ratios of 3.63 to 9.75 ) for death across studies in AMI patients. In conclusion, adrenomedullin is an independent predictor of death in patients with heart failure, as well as MACE and death in patients who have suffered an AMI. Quantification of this peptide might contribute to improved risk stratification in settings of heart failure and myocardial infarction.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of Adrenomedullin in Patients With Heart Failure and With Myocardial Infarction

Yuyun

Narayan

2015

The American Journal of Cardiology

View full text Add to dashboard Cite

show abstract

“…From the perspective of pathophysiology, they are classified into (I) neurohormones (4–9), (II) metabolic hormones/peptides (10–13), (III) cardiac injury markers (14, 15), (IV) oxidative stress markers (16–21), (V) matrix-related markers (22–27), (VI) inflammatory markers (28–31), (VII) renal markers (32), and (VIII) mineral and bone disorder hormones/markers (33–41), as summarized in Table 1.…”

Section: Renocardiovascular Biomarkersmentioning

confidence: 99%

Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease

Niizuma

Iwanaga

Yahata³

et al. 2017

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Mortality among the patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) remains high because of the very high incidence of cardiovascular disease (CVD) such as coronary artery disease, cardiac hypertrophy, and heart failure. Identifying CVD in patients with CKD/ESRD remains a significant hurdle and the early diagnosis and therapy for CVD is crucial in these patients. Therefore, it is necessary for the better management to identify and utilize cardiovascular (CV) biomarkers in profiling CVD risk and enabling stratification of early mortality. This review summarizes current evidence about renocardiovascular biomarkers: CV biomarkers in patients with CKD as well as with ESRD, emphasizing on the emerging biomarkers: B-type natriuretic peptide, cardiac troponins, copeptin, the biomarker of renal injury (neutrophil gelatinase-associated lipocalin), and the mineral and bone disorder hormone/marker (fibroblast growth factor-23). Furthermore, it discusses their potential roles especially in ESRD and in future diagnostic and therapeutic strategies for CVD in the context of managing cardiorenal syndrome.

show abstract

“…Bosselmann et al showed that copeptin and other cardiovascular biomarkers are closely associated with renal function in heart failure. Still, the marker was useful for risk stratification independently of renal function [45]. Also, Choi et al found a standardised mean difference by study region with significant differences in copeptin blood levels, but a positive consistent association of copeptin with poor prognosis [46].…”

Section: Discussionmentioning

confidence: 99%

Copeptin predicts 10-year all-cause mortality in community patients: a 10-year prospective cohort study

Odermatt

Bolliger

Hersberger

et al. 2016

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Background: Copeptin, the C-terminal part of the arginine vasopressin (AVP) precursor peptide, is secreted in response to stress and correlates with adverse clinical outcomes in the acute-care hospital setting. There are no comprehensive data regarding its prognostic value in the community. We evaluated associations of copeptin levels with 10-year mortality in patients visiting their general practitioner (GP) for a respiratory infection included in a previous trial. Methods: This is a post hoc analysis including data from 359 patients included in the PARTI trial. Copeptin was measured in batch-analysis on admission and after 7 days. We calculated Cox regression models and area under the receiver operating characteristic curve (AUC) to assess an association of copeptin with mortality and adverse outcome. Follow-up data were collected by GP, patient and relative tracing through phone interviews 10 years after trial inclusion. Results: After a median follow-up of 10.0 years, mortality was 9.8%. Median admission copeptin levels (pmol/L) were significantly elevated in non-survivors compared to survivors (13.8, IQR 5.9-27.8; vs. 6.3 IQR 4.1-11.5; p < 0.001). Admission copeptin levels were associated with 10-year all-cause mortality [age-adjusted hazard ratio 1.7 (95% CI, 1.2-2.5); p < 0.001, AUC 0.68]. Results were similar for discharge copeptin levels. Copeptin also predicted adverse outcomes defined as death, pulmonary embolism and major adverse cardiac and cerebrovascular events. Conclusions: In a sample of community-dwelling patients visiting their GP for a respiratory infection, copeptin levels were associated with 10-year all-cause mortality. In conjunction with traditional risk factors, this marker may help to better direct preventive measures in this population.

show abstract

Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: A long term follow-up study

Cited by 33 publications

References 31 publications

Prognostic Significance of Adrenomedullin in Patients With Heart Failure and With Myocardial Infarction

Prognostic Significance of Adrenomedullin in Patients With Heart Failure and With Myocardial Infarction

Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease

Copeptin predicts 10-year all-cause mortality in community patients: a 10-year prospective cohort study

Contact Info

Product

Resources

About